Salari N,Morddarvanjoghi F,Abdolmaleki A,Rasoulpoor S,Khaleghi AA,Hezarkhani LA .2023 .The global prevalence of myocardial infarction: a systematic review and meta-analysis. BMC Cardiovasc Disord, 10(1) : 206.
Nielsen TJ,Vestergaard M,Christensen B,Christensen KS,Larsen KK .2013 .Mental health status and risk of new cardiovascular events or death in patients with myocardial infarction: a populationbased cohort study. -003045, 10(8) : .
Guha A,Dey AK,Al-Kindi S,Miller PE,Ghosh AK,Banerjee A .2020 .Socio-Economic Burden of Myocardial Infarction Among Cancer Patients. Am J Cardiol, 11 : 16-22.
Jiao Y,Fu X,Liu Q,Zhang W. .2022 .The effects of AnisodamineTirofiban Combined Therapy in acute myocardial infarction treated with Percutaneous Coronary Intervention (PCI). Pak J Med Sci, 10(7) : 5410-1753.
Liu Y,Zhang L,Yang Y .2020 .Tirofiban hydrochloride sodium chloride injection combined with cardiovascular intervention in the treatment of Acute Myocardial Infarction. Pak J Med Sci, 10(2) : 1005-58.
Chen GX,Wang HN,Zou JL,Yuan XX .2020 .Effects of intracoronary injection of nicorandil and tirofiban on myocardial perfusion and short-term prognosis in elderly patients with acute STsegment elevation myocardial infarction after emergency PCI. World J Emerg Med, 03(3) : 8642-163.
Tang X,Li R,Ma L,Zhang T .2022 .Application of tirofiban in patients with acute myocardial infarction complicated with diabetes and undergoing emergency interventional therapy. Pak J Med Sci, 10(1) : 4545-178.
Kang SX,Meng XM,Li J .2022 .Effect of Tirofiban Injection on vascular endothelial function, cardiac function and inflammatory cytokines in patients with acute myocardial infarction after emergency Percutaneous Coronary Intervention. Pak J Med Sci, 10(1) : 4413-15.
Yang M,Huo X,Miao Z,Wang Y.,Platelet Glycoprotein Y. .2019 .IIb/IIIa Receptor Inhibitor Tirofiban in Acute Ischemic Stroke. Drugs, 10(5) : 515-529.
Denny O,Woodruff AE,Mills K,Chilbert MR,Pharmacol J Cardiovasc .2022 .Comparison of Ischemic and Bleeding Events Between Short-Duration Versus Long-Duration Tirofiban Regimens in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention. , 10(1) : 56-61.
Ciliberti G,Compagnucci P,Urbinati A,Bianco F,Stronati G,Lattanzi S .2020 .Myocardial Infarction Without Obstructive Coronary Artery Disease (MINOCA): A Practical Guide for Clinicians. Curr Probl Cardiol, 10(3) : 100761.
Appleby MA,Michaels AD,Chen M,Michael CG .2000 .Importance of the TIMI frame count: implications for future trials. Curr Control Trials Cardiovasc Med, 10(1) : 31-34.
Fabris E,Ten Berg JM,Hermanides RS,Ottervanger JP,Dambrink JHE,Gosselink AM .2020 .NT-proBNP level before primary PCI and risk of poor myocardial reperfusion: Insight from the On-TIME II trial. Am Heart J, 12 : 78-85.
Lei Z,Xiaoming Z,Yan H,Ming ZX,Med ZX .2015 .Analysis of the Best Timing for Applying Tirofiban in PCI Operation for the Patients with ST Segment Elevation Myocardial Infarction. , 10(1) : 382-387.
Zhang J,Ding G .2021 .Improved Cardiac Function and Attenuated Inflammatory Response by Additional Administration of Tirofiban during PCI for ST-Segment Elevation Myocardial Infarction Patients. Evid Based Complement Alternat Med, 10 : .
Guo YZ,Zhao ZW,Li SM,Chen LL .2021 .Clinical efficacy and safety of tirofiban combined with conventional dual antiplatelet therapy in ACS patients undergoing PCI. Sci Rep, 10(1) : 17144.
Zou X,Huang H. .2016 .The Infuence of Different Time Application of Tirofiban on the Immediate Targetangiography and Myocardial Injury in Patients with Acute ST segment Elevation Myocardial Infarction undergoing Percutaneous Coronary Intervention. Chinese Journal of Integrative Medicine on Cardio/ Cerebrovascular Disease, 22 : 1349-2606.
Zheng X .2015 .Comparative analysis of different application time of tirofiban in emergent interventional treatment of acute myocardial infarction on coronary blood flow and recent prognosis. China Practical Medical, 05 : 5547-25.
Zeng Q,Zhang LD,Wang W. .2020 .A meta-analysis of randomized controlled trials investigating tirofiban combined with conventional drugs by intracoronary administration for no-reflow prevention. Anatol J Cardiol, 10(1) : 7-16.
Sun B,Liu Z,Yin H,Wang T,Chen T,Yang S .2017 .Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes: A meta-analysis of randomized controlled trials. Medicine (Baltimore), 10(40) : .
Salama AM,Khalil WA,Al-Zaky M,Abdallah SH,Kandil NT,Abdelsabour A .2020 .-208a: a Good Diagnostic Marker and a Predictor of no-Reflow in STEMI Patients Undergoing Primary Percutaneuos Coronary Intervention. J Cardiovasc Transl Res, 10(6) : 988-995.
Wang G,Wang C,Huang Z,Sun S,Chen Y .2023 .Exosomal circ0020887 and circ-0009590 as novel biomarkers for the diagnosis and prediction of short-term adverse cardiovascular outcomes in STEMI patients. Open Med (Wars), 10(1) : 20230807.
Zhao Z,Qiu P,Lu H,Yin M,Liu X,Li F .2020 .Near-infrared -triggered release of tirofiban from nanocarriers for the inhibition of platelet integrin αIIbβ3 to decrease early-stage neointima formation. Nanoscale, 10(7) : 4676-4685.